CLINICAL_TRIALS
trial_result
· 2014-07-21
Clinical Trial Update: Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease [Phase 3]
Summary
A Phase 3 study of vedolizumab (MLN0002) in patients with moderate to severe Crohn's disease has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-07-21